Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma

BACKGROUND: B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T-cell therapy is an emerging treatment option for multiple myeloma. The aim of this systematic review and meta-analysis was to determine its safety and clinical activity and to identify factors influencing these o...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Hematol Oncol
Asıl Yazarlar: Roex, Gils, Timmers, Marijke, Wouters, Kristien, Campillo-Davo, Diana, Flumens, Donovan, Schroyens, Wilfried, Chu, Yiwei, Berneman, Zwi N., Lion, Eva, Luo, Feifei, Anguille, Sébastien
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2020
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7713173/
https://ncbi.nlm.nih.gov/pubmed/33272302
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-01001-1
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller